Explainer
Chikungunya explained: symptoms, the 2025 outbreaks and vaccines
Chikungunya is a viral disease spread by Aedes mosquitoes that causes sudden fever and often severe joint pain, which can last for months or even years.[1][2][3] WHO counted 445,271 cases and 155 deaths in 40 countries from January to September 2025, including large outbreaks in La Réunion and in Guangdong, China.[4][5][6] There is no specific antiviral treatment.[7] In August 2025 the US FDA suspended the licence of Ixchiq, the first chikungunya vaccine, over safety concerns, while a second vaccine, Vimkunya, remains licensed in the US.[8][9]
This page explains chikungunya for general readers. It is not medical advice. If you have a fever and joint pain after being in an area with chikungunya, talk to a clinician.
Chikungunya is a viral disease caused by the chikungunya virus, an alphavirus spread by mosquitoes.[1] The name comes from a word in the Kimakonde language of southern Tanzania that describes the bent posture of people with severe joint pain.[1] The virus was first identified in Tanzania in 1952. Outbreaks have become more frequent and widespread since 2004, and the virus has now been found in more than 110 countries.[10]
How it spreads
Chikungunya is spread by the bites of infected female mosquitoes, most commonly Aedes aegypti and Aedes albopictus. These species also carry dengue and Zika, and they bite mainly during daylight hours.[2] See dengue explained for the closely related mosquito-borne illness.
Symptoms and who gets seriously ill
Symptoms usually start 4 to 8 days after an infected bite, though the range is 2 to 12 days. Illness begins with sudden fever, often with severe joint pain. The pain usually lasts a few days but can go on for weeks, months or even years. Joint swelling, muscle pain, headache, nausea, tiredness and rash are also common.[3] Because the symptoms look like dengue and Zika, chikungunya is easy to misdiagnose.[11]
Most people recover fully. Severe illness and deaths are rare and usually affect newborns or older people with other health conditions. People who have recovered are likely to be immune to future infection.[12]
Treatment and prevention
There is no specific antiviral treatment. WHO says care focuses on easing fever and joint pain, drinking plenty of fluids and resting. It advises against non-steroidal anti-inflammatory drugs until dengue has been ruled out, because they can increase the risk of bleeding.[7]
Avoiding mosquito bites is the best protection. WHO recommends clothing that covers the skin, screens on windows and doors, and repellents containing DEET, IR3535 or icaridin, used as the label directs. Emptying and cleaning water containers every week helps remove breeding sites.[13]
The 2025 outbreaks
WHO reported 445,271 suspected and confirmed chikungunya cases and 155 deaths from 40 countries between 1 January and 30 September 2025. It said uneven trends across regions made it hard to call this a global rise, and the Americas reported the most cases.[4] In the Americas, 14 countries reported 228,591 suspected cases and 115 deaths by 20 September, and Brazil accounted for nearly 96% of the region’s cases and deaths.[14]
La Réunion, the French department in the Indian Ocean, reported 54,517 confirmed cases and 40 deaths by 14 September 2025, its first local spread since 2014.[5] By mid-September, mainland France had recorded 479 locally acquired cases and Italy 205. WHO linked France’s early, larger season to the Indian Ocean epidemic and to a strain well adapted to the Aedes albopictus mosquito.[15] In China, Guangdong province reported 16,452 locally transmitted cases by 27 September, mainly in Foshan. WHO called it the largest documented chikungunya outbreak in China.[6]
Vaccines and the Ixchiq suspension
On 9 November 2023 the US Food and Drug Administration approved Ixchiq, the first chikungunya vaccine, for adults at higher risk of exposure. It used the accelerated approval pathway, which required confirmatory studies to verify the vaccine’s clinical benefit.[16]
In May 2025 the FDA and CDC recommended pausing its use in people aged 60 and over while reports of serious adverse events were investigated. The FDA lifted that pause on 6 August 2025 with updated labelling and stronger warnings.[17] On 22 August 2025 the FDA suspended Ixchiq’s US licence. It said the vaccine appeared to cause chikungunya-like illness in some recipients, and that one death from encephalitis was directly attributable to it. It added that its benefit-risk analysis broadly did not show benefits outweighing risks.[8] The FDA now lists Ixchiq as permanently discontinued. It says Valneva has stopped manufacturing the vaccine and asked for its US licence to be revoked.[18]
A second vaccine, Vimkunya, is licensed in the US for people aged 12 and older.[9] WHO says the two chikungunya vaccines are not yet widely available or in widespread use, and it is reviewing trial and post-marketing data before making any recommendations.[19] For travel planning, see travel vaccines explained.
Read next
Dengue explained: symptoms, warning signs, vaccines and spread
What dengue is, why a second infection can be worse, the warning signs of severe dengue, record case counts, and where the dengue vaccine fits.
Questions readers ask
How do you catch chikungunya?
From the bite of an infected female mosquito, most commonly Aedes aegypti or Aedes albopictus. These are the same mosquitoes that carry dengue and Zika, and they bite mainly in the daytime.[2]
What are the symptoms of chikungunya?
Sudden fever, often with severe joint pain, usually 4 to 8 days after an infected bite. Joint swelling, muscle pain, headache, nausea, tiredness and a rash are also common. The joint pain usually lasts a few days but can last weeks, months or years.[3]
Is chikungunya deadly?
Rarely. WHO says severe illness and deaths usually happen in newborns or in older people with other health problems. Most people recover fully and are then likely to be immune.[12]
Is there a treatment for chikungunya?
There is no specific antiviral drug. Care focuses on relieving fever and pain, fluids and rest. WHO advises avoiding anti-inflammatory painkillers until dengue has been ruled out because they can raise the risk of bleeding. Ask a clinician which medicines are right for you.[7]
Why was the Ixchiq vaccine suspended?
On 22 August 2025 the FDA suspended Ixchiq's US licence, saying the vaccine appeared to cause chikungunya-like illness in some recipients and that one death from encephalitis was directly attributable to it. The FDA said its benefit-risk analysis broadly did not show benefits outweighing risks. The manufacturer has since stopped making it and asked for the licence to be revoked.[8][18]
Sources
· 19 claims from 2 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
WHO describes chikungunya as a mosquito-borne viral disease caused by the chikungunya virus, an RNA virus in the alphavirus genus; the name comes from a Kimakonde word from southern Tanzania describing the bent posture of people with severe joint pain. confirmedas of 2026-11-14
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- [2]
Chikungunya is spread by the bites of infected female mosquitoes, most commonly Aedes aegypti and Aedes albopictus, which also carry dengue and Zika and bite mainly in daylight. confirmedas of 2026-11-14
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- [3]
Symptoms usually begin 4 to 8 days (range 2 to 12) after an infected bite, with sudden fever and often severe joint pain that usually lasts a few days but can last weeks, months or years; joint swelling, muscle pain, headache, nausea, fatigue and rash are also common. confirmedas of 2026-11-14
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- [4]
WHO reported that between 1 January and 30 September 2025, 445,271 suspected and confirmed chikungunya cases and 155 deaths were reported from 40 countries, with the Americas reporting the most cases; WHO said uneven regional trends made it hard to call this a global rise. confirmedas of 2025-10-03
- Chikungunya virus disease - Global situation (Disease Outbreak News) · World Health Organization · Primary source · 2025-10-03 (retrieved 2026-11-14)
- Chikungunya virus disease - Global situation (Disease Outbreak News) · World Health Organization · Primary source · 2025-10-03 (retrieved 2026-11-14)
- Chikungunya virus disease - Global situation (Disease Outbreak News) · World Health Organization · Primary source · 2025-10-03 (retrieved 2026-11-14)
- [5]
La Réunion, a French overseas department in the Indian Ocean, reported 54,517 confirmed chikungunya cases and 40 deaths in 2025 as of 14 September, its first local transmission since 2014. confirmedas of 2025-10-03
- Chikungunya virus disease - Global situation (Disease Outbreak News) · World Health Organization · Primary source · 2025-10-03 (retrieved 2026-11-14)
- Chikungunya virus disease - Global situation (Disease Outbreak News) · World Health Organization · Primary source · 2025-10-03 (retrieved 2026-11-14)
- [6]
As of 27 September 2025, Guangdong Province in China had reported 16,452 locally transmitted chikungunya cases, mainly in Foshan, which WHO called the largest documented chikungunya outbreak in China. confirmedas of 2025-10-03
- Chikungunya virus disease - Global situation (Disease Outbreak News) · World Health Organization · Primary source · 2025-10-03 (retrieved 2026-11-14)
- Chikungunya virus disease - Global situation (Disease Outbreak News) · World Health Organization · Primary source · 2025-10-03 (retrieved 2026-11-14)
- [7]
There is no specific antiviral treatment for chikungunya; WHO says care focuses on fever and pain relief, fluids and rest, and that non-steroidal anti-inflammatory drugs should be avoided until dengue has been ruled out because they can increase the risk of bleeding. confirmedas of 2026-11-14
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- [8]
On 22 August 2025 the FDA suspended the US licence for Ixchiq, citing serious safety concerns including chikungunya-like illness in vaccine recipients and one death from encephalitis it attributed directly to the vaccine; it said its benefit-risk analysis broadly did not show benefits outweighing risks. confirmedas of 2025-08-22
- FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License: FDA Safety Communication · US Food and Drug Administration · Primary source · 2025-08-22 (retrieved 2026-11-14)
- FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License: FDA Safety Communication · US Food and Drug Administration · Primary source · 2025-08-22 (retrieved 2026-11-14)
- FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License: FDA Safety Communication · US Food and Drug Administration · Primary source · 2025-08-22 (retrieved 2026-11-14)
- [9]
The FDA lists Vimkunya as a licensed vaccine for preventing disease caused by chikungunya virus in people aged 12 and older. confirmedas of 2026-11-14
- VIMKUNYA · US Food and Drug Administration · Primary source (retrieved 2026-11-14)
- [10]
According to WHO, the virus was first identified in Tanzania in 1952; outbreaks have become more frequent and widespread since 2004, and the virus has been identified in more than 110 countries in Asia, Africa, Europe and the Americas. confirmedas of 2026-11-14
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source · Overview: 'more than' is written as '>110' on the page (retrieved 2026-11-14)
- [11]
WHO says chikungunya symptoms resemble those of dengue and Zika, which makes it easy to misdiagnose. confirmedas of 2026-11-14
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- [12]
Most people recover fully; WHO says severe illness and deaths are rare and usually occur in newborns or in older people with other health problems, and that people who recover are likely to be immune to future infection. confirmedas of 2026-11-14
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- [13]
WHO says avoiding mosquito bites is the best protection, recommending clothing that covers the skin, window and door screens, and repellents containing DEET, IR3535 or icaridin used as labelled; reducing breeding sites by emptying water containers weekly is the main community measure. confirmedas of 2026-11-14
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- [14]
In the Americas, 14 countries had reported 228,591 suspected chikungunya cases and 115 deaths by 20 September 2025, with Brazil accounting for nearly 96% of the region's cases and deaths. confirmedas of 2025-10-03
- Chikungunya virus disease - Global situation (Disease Outbreak News) · World Health Organization · Primary source · 2025-10-03 (retrieved 2026-11-14)
- Chikungunya virus disease - Global situation (Disease Outbreak News) · World Health Organization · Primary source · 2025-10-03 (retrieved 2026-11-14)
- [15]
As of 15 September 2025, France had recorded 479 locally acquired chikungunya cases in 54 clusters and Italy 205 in four clusters; WHO linked France's early, larger season to the Indian Ocean epidemic and a strain well adapted to Aedes albopictus. confirmedas of 2025-10-03
- Chikungunya virus disease - Global situation (Disease Outbreak News) · World Health Organization · Primary source · 2025-10-03 (retrieved 2026-11-14)
- Chikungunya virus disease - Global situation (Disease Outbreak News) · World Health Organization · Primary source · 2025-10-03 (retrieved 2026-11-14)
- [16]
On 9 November 2023 the FDA approved Ixchiq, the first chikungunya vaccine, for adults at increased risk of exposure, under the accelerated approval pathway that required confirmatory studies to verify clinical benefit. confirmedas of 2023-11-09
- FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus · US Food and Drug Administration · Primary source · 2023-11-09 (retrieved 2026-11-14)
- FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus · US Food and Drug Administration · Primary source · 2023-11-09 (retrieved 2026-11-14)
- FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus · US Food and Drug Administration · Primary source · 2023-11-09 (retrieved 2026-11-14)
- [17]
Before the suspension, the FDA and CDC had recommended pausing Ixchiq in people aged 60 and over on 9 May 2025 while serious adverse event reports were investigated; the FDA lifted that pause on 6 August 2025 with updated labelling and stronger warnings. confirmedas of 2025-08-22
- FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License: FDA Safety Communication · US Food and Drug Administration · Primary source · 2025-08-22 (retrieved 2026-11-14)
- FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License: FDA Safety Communication · US Food and Drug Administration · Primary source · 2025-08-22 (retrieved 2026-11-14)
- [18]
The FDA lists Ixchiq as permanently discontinued in the US, saying Valneva has stopped manufacturing it and has requested voluntary revocation of its US licence. confirmedas of 2026-11-14
- CBER-Regulated Products: Permanent Discontinuations · US Food and Drug Administration · Primary source (retrieved 2026-11-14)
- [19]
WHO says two chikungunya vaccines have received regulatory approvals or recommendations in several countries but are not yet widely available or in widespread use, and that it is reviewing trial and post-marketing data before making possible recommendations. confirmedas of 2026-11-14
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
- Chikungunya fact sheet · World Health Organization · Primary source (retrieved 2026-11-14)
Revision history (1)
- Page created.
Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: Nov 14, 2027.
Cite this page
"Chikungunya explained: symptoms, the 2025 outbreaks and vaccines." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/chikungunya-explained
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.